# Vera Therapeutics (VERA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/VERA
## Company Profile
- Ticker: VERA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 32.02 USD
- Market cap: 2243933579.04 USD
- Last updated: 2026-08-06
## Business Overview
### Kidney-Disease Biologics
Vera Therapeutics develops therapies for immune-mediated kidney diseases. Its lead program targets B-cell survival signals implicated in abnormal antibody production.
### Atacicept
Atacicept is a recombinant TACI fusion protein that binds BAFF and APRIL. It is under Priority Review for accelerated approval in adults with IgA nephropathy.
### Commercial Transition
Vera is preparing to move from clinical development into a commercial-stage model centered on atacicept, subject to FDA approval.
## Why The Stock Is Moving

As of Aug 6, 2026, VERA closed up 5.50% at $32.02. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA PDUFA target action date for atacicept on July 7, 2026.
- Potential U.S. launch of atacicept around mid-2026, subject to approval.

## Recent News
- 2026-07-10 20:05 EST — [Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-81ab24dd) — Source: Vera Therapeutics
- 2026-07-09 12:00 EST — [Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner](https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-appointment-of-nancy-boman-as-chief-regulatory-offic-3bddef92) — Source: Vera Therapeutics
- 2026-07-07 16:37 EST — [Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy](https://biopharmsignal.com/news/VERA/vera-therapeutics-receives-fda-accelerated-approval-for-trutakna-for-adult-patie-79e89de4) — Source: Vera Therapeutics
- 2026-06-02 11:00 EST — [Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy](https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-alignment-with-u-s-fda-on-earlier-origin-phase-3-ana-53ed5fb6) — Source: Vera Therapeutics
- 2026-05-07 11:30 EST — [Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/VERA/vera-therapeutics-provides-business-update-and-reports-first-quarter-2026-financ-6cce7130) — Source: Vera Therapeutics